BanseogGLOBAL
Menu
INTELLIGENCEPhysical AILIVESemiconductorPREPARINGBioLIVEPRODUCTCareer RadarLIVELANGUAGE
KOEN日本
BANSEOGBanseog SearchABOUTHire in KoreaEXECUTE
← Bio Talent Intelligence

BANSEOG BIO TALENT INTELLIGENCE

BIOPHARMA · COMPANY INTELLIGENCE

CHUGAI
PHARMACEUTICAL

We look for people who turn outside possibilities into proprietary capability, amplify them through strong networks, and recycle weak paths into better search.

TALENT PATTERN · 01The scarce skill may be turning external science into capability the company can still use after the partner is gone.
Company & HR — who should we look for? →Talent & Career — what should I build next? →
6 roles & capabilities observed4 business & hiring changes observed3 Talent Patterns published

TALENT PATTERNS

See which experience may become scarce first.

01EXTERNAL-TO-PROPRIETARY

TALENT CAPABILITY

External-to-Proprietary

Capability Internalizer

The capability to turn outside science, technology and targets into methods, platforms and decision rules that remain inside the company.

Having many external collaborations is different from creating reusable proprietary capability from them.

Core capability
  • External Science Evaluation
  • Internalization
  • Proprietary Method Building
  • Reusable Knowledge
Experience that strengthens it
  • Discovery Research
  • Alliance Context
  • IP / Technical Evaluation
  • Cross-team Translation

The scarce skill may be turning external science into capability the company can still use after the partner is gone.

We track experience that converts external technologies, targets and research into reusable internal methods, platforms and decision rules rather than stopping at access or collaboration.

Why nowTOP I 2030 explicitly connects stronger Open Innovation with proprietary technologies and in-house R&D output by combining outside technologies and targets with Chugai strengths.

Company & HR

Who left an internal capability behind after bringing in an external technology?

Who should we look at first?Discovery / Open Innovation / Technical Alliance plus ownership of internal platforms, methods or decision rules
Where should we look?

Look across biotech platforms, academia-to-pharma translation, technical licensing, external research and scientific partnerships where the person owned internalization, not only access.

What should we do next?

Test what remained after the collaboration ended and whether another internal team could reuse it.

Hiring playbook

Search rule

Look beyond Open Innovation titles for evidence that outside technology became an internal assay, platform, workflow or decision rule.

Evidence to test in interview

Ask what remained after the partner or university engagement ended and who could reuse it internally.

Build internally

Give Discovery and Alliance talent ownership of internal method creation, not only external scanning.

Request analysis of this talent market →
View evidence5
Roles & capabilities
Discovery Research
Research Science
Alliance Management
02PRUNE-TO-RE-SEARCH

TALENT CAPABILITY

Prune-to-Re-search

Discovery Selector

The capability to integrate multiple evidence types early, stop or redesign weak candidates and turn the learning back into better search.

Creating a good candidate is different from identifying a weak candidate early enough to protect resources and improve the next program.

Core capability
  • Candidate Selection
  • Advance / Kill / Redesign
  • Cross-evidence Judgment
  • Learning Recycle
Experience that strengthens it
  • DMPK / Safety
  • Translational Context
  • Portfolio Judgment
  • Research Data

The scarce skill may be knowing what to stop early—and turning that failure into a better next search.

We track experience that combines efficacy, safety, DMPK and physical-property evidence early enough to advance, kill or redesign candidates and recycle learning into the next search.

Why nowChugai’s Quality-Centric Drug Discovery aims for the highest-quality development candidates achievable with current technology while maintaining a high clinical-development success rate. More R&D output makes selection quality increasingly important.

Company & HR

How do we find people who have stopped the right project—not only people with successful projects?

Who should we look at first?Discovery / Research Science plus candidate Go/No-Go experience using DMPK, Safety, Translational or Early Development evidence
Where should we look?

Look beyond Discovery scientists to DMPK, Safety, Translational, Early Development and Technical Portfolio talent that has materially changed candidate selection.

What should we do next?

Ask for the candidate they stopped or redesigned best, the warning signal, the decision timing and what learning changed the next program.

Hiring playbook

Search rule

Look beyond successful-candidate counts for evidence of candidate kill/redesign decisions and learning reuse.

Evidence to test in interview

Ask for the strongest stop decision the person made and what evidence changed the next program.

Build internally

Give Discovery talent early Go/No-Go ownership that explicitly includes DMPK, Safety and Translational evidence.

Request analysis of this talent market →
View evidence5
Roles & capabilities
Discovery Research
Research Science
AI / ML Engineering
03ALLIANCE-TO-AUTONOMY

TALENT CAPABILITY

Alliance-to-Autonomy

Autonomous Alliance Builder

The capability to use a powerful global partner while keeping core decision rights and repeatable execution inside the company.

Working with a global partner for years is different from increasing what the internal organization can decide and execute independently.

Core capability
  • Alliance Leverage
  • Decision-right Design
  • Capability Internalization
  • Multi-region Execution
Experience that strengthens it
  • Global Business
  • Commercial Context
  • Co-development
  • Governance

The scarce skill may be using a powerful partner while leaving more independent execution inside the company.

We track experience that uses a global partner’s resources and network while preserving internal science, decision rights and repeatable execution capability.

Why nowRoche owns 59.89% of Chugai, yet the alliance explicitly preserves Chugai management autonomy and listed-company status while Roche amplifies global development and commercial reach.

Company & HR

Who has used a global partner without outsourcing the company’s core judgment to that partner?

Who should we look at first?Alliance / Global Business / Clinical / Commercial plus decision-right design, internal capability building or multi-region execution
Where should we look?

Look beyond Roche-linked talent to big-pharma/biotech co-development, global alliance, licensing and multi-region development or launch experience with real internal ownership.

What should we do next?

Test what partner resource was used and which decisions, methods or operating responsibilities remained or moved inside the company.

Hiring playbook

Search rule

Look beyond alliance tenure for the decision rights and capabilities the person left inside the company.

Evidence to test in interview

Ask what partner-owned work became internally repeatable and which core judgment was deliberately kept inside.

Build internally

Add internal-capability building and decision-right ownership to Alliance / Global Business roles.

Request analysis of this talent market →
View evidence4
Roles & capabilities
Alliance Management
Global Business
Commercial

CURRENT EVIDENCE

Start with what is currently observed.

Current roles & capabilities

Discovery ResearchContinuing signal
Research ScienceContinuing signal
Alliance ManagementContinuing signal
Global BusinessContinuing signal
CommercialContinuing signal
AI / ML EngineeringContinuing signal

Business & hiring changes

Date not confirmed · Hiring changeHiring changeSource ↗
Date not confirmed · Pipeline changePipeline changeSource ↗
Date not confirmed · Pipeline changePipeline changeSource ↗
2002-10-01 · PartnershipPartnershipSource ↗
BANSEOG ANALYSISBanseog analysis connects the currently observed evidence.

CURRENT TALENT MARKET

Then see the talent market moving around it.

TALENT & CAREER

How far can my experience transfer?

No evidence-backed adjacent career path is currently linked.

COMPANY & HR

Who else is looking at the same talent?

No evidence-backed talent-competitor relationship is currently linked.